RxDoctor Payments Data

Anne Yacoub, MD

Neurology · Baltimore, MDNPI 1134672918

Payments from drug & device makers

$12,321in general payments, 2019–2025

Across 27 payments — averaging $456.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$10K
  • Amneal Pharmaceuticals LLC$2K
  • Pfizer$249
  • Sanofi$125
  • EMD Serono, Inc.$87
  • Lundbeck LLC$15

What the payments were for

  • Consulting fees$9,88880%
  • Travel & lodging$1,0398%
  • Food & beverage$1,30811%
  • Education$871%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie20$9,596
Amneal Pharmaceuticals LLC1$2,250
Pfizer2$249
Sanofi1$125
EMD Serono, Inc.2$87
Lundbeck LLC1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,321 in reported general payments places this provider in the 70th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$29,240
Medicare patients
119
Services billed
219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant39$38,570
Emgality PenGalcanezumab-Gnlm27$28,397
Aimovig AutoinjectorErenumab-Aooe22$16,699
Nurtec OdtRimegepant Sulfate14$14,376
Gabapentin37$859
RizatriptanRizatriptan Benzoate20$190
Ondansetron OdtOndansetron12$24

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$9,596$38,57039 claims
PfizerNurtec Odt$249$14,37614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 442 neurology providers in Maryland.

Other neurology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →